Gemin X Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel, targeted cancer therapeutics. Its lead candidate, Obatoclax (GX15-070), is being advanced toward a Phase 3 pivotal trial in small cell lung cancer; the recent financing will support preparations for that trial. In March 2010 the company completed enrollment in an ongoing Phase 2b trial of obatoclax being conducted at more than 60 cancer centers, primarily in the United States and Europe. Gemin X also has other clinical programs, including GMX1777, a novel inhibitor of NAD+ synthesis that has completed a Phase 1 study. The company completed an $8M Series E financing and retains multiple clinical development programs in its pipeline. Founded in 1998, Gemin X has drug development and executive headquarters in Malvern, Pennsylvania and research and development in Montréal, Canada. Gemin X Pharmaceuticals is developing targeted cancer therapeutics, with a lead product candidate obatoclax (GX15-070) that showed positive Phase 1b data in small cell lung cancer (SCLC). The company is running an ongoing Phase 2b trial evaluating obatoclax in combination with standard chemotherapy at over 60 cancer centers, primarily in the United States and Europe. Gemin X also has several other clinical development programs, including an innovative pan Bcl-2 inhibitor and GMX1777, a novel inhibitor of NAD+ synthesis that has completed a Phase 1 study. The company is clinical-stage and advancing multiple oncology programs through early and mid-stage trials. Financially, Gemin X recently closed a $16M Series D financing round, with an option for certain current investors to invest an additional $4M. The financing follows the positive Phase 1b data for its lead candidate and is intended to support continued clinical development.

Total raised

$24M

Funding rounds

2

Latest round

Series E

Latest activity

Aug 2010